Evidence of a hepatoprotective effect of IGF-I derives also from human studies, showing that growth hormone replacement therapy reverts liver damage in GH deficient patients, for whom NAFLD is an important complication of the disease [18–20]. This evidence concerns the gene IGF1 and metabolic dysfunction-associated steatotic liver disease.